Clinical and molecular characterization of <i>AXL</i> in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data.

ABSTRACT:

Background

AXL dysregulation is associated with both intrinsic resistance in tumor cells and reprogramming of the immune microenvironment. However, it is still unclear which patients would benefit from AXL-targeting therapies. We conducted a clinical and molecular characterization of AXL in colorectal cancer (CRC).

Methods

This study integrated real-world molecular profiling (Caris cohort; n=24,257) and randomized clinical trial data (phase III Cancer and Leukemia Group B/Southwest Oncology Group (CALGB/SWOG) 80405; n=433) to assess AXL messenger RNA expression in patients with CRC. Tumor samples underwent RNA sequencing and analysis of the immune microenvironment. AXL expression was categorized into tertiles. We assessed associations between mole

SUBMITTER: Ashouri K 

PROVIDER: S-EPMC12719898 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature